PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Study Identifier:
D6780C00004
ClinicalTrials.gov Identifier:
NCT06607627
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Recruiting

Study Details

Medical Condition
  • Generalized Myasthenia Gravis
  • Unmapped
Study Drug
    Date
    Nov 2024 - Apr 2027
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: 6 - 17 Years
    Requirements Information
    Sex
    Female & Male
    Age
    6 - 17 Years

    Study Details

    Medical Condition
    • Generalized Myasthenia Gravis
    • Unmapped
    Study Drug
      Date
      Nov 2024 - Apr 2027
      Phase 1
      Phase 2
      Phase 3
      Phase 4
      N/A
      Patient Requirements
      Sex: Female & Male
      Age: 6 - 17 Years years
      Requirements Information

      Protocol Summary

      The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

      Trial Locations

      Location
      Status
      Location
      Research Site
      Washington, District of Columbia, United States, 20010
      Status
      Recruiting
      Location
      Research Site
      Norfolk, Virginia, United States, 23507
      Status
      Recruiting
      Location
      Research Site
      Joinville, Brazil, 89202-451
      Status
      Recruiting
      Location
      Research Site
      Salvador, Brazil, 41253-190
      Status
      Recruiting
      Location
      Research Site
      Sao Jose Do Rio Preto, Brazil, 15090-000
      Status
      Recruiting
      Location
      Research Site
      Sao Paulo, Brazil, 05403-000
      Status
      Recruiting
      Go to page